Takara Bio entered into a licensing agreement relating to Oncolytic Virus “Canerpaturev” with Dong-A ST, South Korea August 22, 2018October 19, 2019 by / Share This.....LinkedinTwitterFacebookGoogleEmail http://ir.takara-bio.co.jp/en/news_all/news_IR/auto_20180822499609/pdfFile.pdf Related News: [Delayed]Takara Bio Announces Transfer of SAKIGAKE…Takara Bio Group Formulated “Medium-Term Management…Takara Bio Report 2022Takara Bio Report 2023Bruker Announces Successful Installation of 1.2 GHz…U.S. Centers for Disease Control Guidance Includes…
